FDAnews
www.fdanews.com/articles/172867-teva-announces-us-availability-of-zecuity-migraine-patch-system

Teva Announces U.S. Availability of Zecuity Migraine Patch System

September 1, 2015

Teva Pharmaceutical Industries Ltd. Has announced the U.S. availability of Zecuity, a patch system designed to provide relief from migraine.

The single-use device, which delivers sumatriptan through the skin, is designed to be worn for a four-hour period either on the upper arm or thigh.

A clinical study of the device found that 18 percent of those using Zecuity experienced no headache pain after two hours of its application, versus only 9 percent of those using a non-medicated patch system, according to the company.

Zecuity is available by prescription through specialty pharmacies in the U.S. — Michael Cipriano